Rhythm Pharmaceuticals Announces New Employment Inducement Grants
GlobeNewswire
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical..
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical..
During the R&D event for investors, Rhythm Pharmaceuticals Inc RYTM released new topline data from its Phase 3 pediatrics trial..
· Developing the first gene therapy to treat diseases caused by cilia dysfunction
· AXV101 targets retinal dystrophy for..